← Back to patent-cliff list
Nerandomilast
Tier C — Watch / tradeNerandomilast
Boehringer Ingelheim
Originator
2025
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：PDE4B
Brand：Jascayd
Indications (approved)：Idiopathic pulmonary fibrosis, Interstitial lung disease, Pulmonary fibrosis
Regional status
US
Approved
2025-10-07
EU
Approved
2026-07-15
China
Approved
2025-10-21
Japan
Approved
2026-05-18
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Nerandomilast?
Approved indications include: Idiopathic pulmonary fibrosis, Interstitial lung disease, Pulmonary fibrosis.
When does the Nerandomilast patent expire?
No public expiry year is available for Nerandomilast yet; this page updates once verified.
How do I get a quote for Nerandomilast intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01